The Siegall’s ambitions are manifested in his aspiration to go past the focus of biotech’s drug development towards taking care of all complexities of the worldwide market for its new drugs. This is a perfect repeat of what the company did during its earlier years when it sold its global commercial rights to Takeda Oncology to get funds to research Adcetris. Once he had learned about the international markets through its collaboration with Takeda, Siegall opened an office in Switzerland to let Seattle genetics conduct its global marketing.
In another emblem to its great determination to the international market, Siegall presented a proposal to utilize $2 billion to purchase the worldwide rights and commercialize a cancer drug established by Immunomedics located in New Jersey. However, Siegall was forced to withdraw the offer in May when a judge made a verdict that the transaction will not go through since there was an unrelated tussle for management over the Immunomedics’ board. However, the struggle signaled the commitment of Seattle genetics to utilize its understanding of oncology to obtain the rights to sell the new drugs in the global market.
The company has been focusing on the particular type of drug called an antibody-drug conjugate, or ADC. In most cases, the drug aims the protein molecule that triggers an immunize system to produce antibodies. The antigens attach themselves to the outside of cancer cells and other deadly disease and deliver a toxin in the cell to destroy them. The role of the ADC is to provide a payload to kill the cancer cells while not having a negative impact on the normal tissues. Typically, the approach significantly lessens the collateral damage that can result in healthy cells in when a patient is going through the traditional chemotherapy and radiation. In all the 11 drugs found in the Seattle Genetics pipeline, Siagall claims that four of them have massive potential for the most instant sales.
About Clay Siegall
Currently, Clay Siegall works as the president, CEO of Seattle Genetics, a biotech firm that specializes in the development and commercialization of innovative antibody related therapies for the cure of cancer. He is also the co-founder of the company that was established in 1998. Before engaging in Seattle Genetics, Siagall served the Bristol-Myers Squibb Pharmaceutical research institute from 1991 to 1997. He also worked at national cancer institute and national institute of health from 1988 to 1991. Dr. Siagall obtained a B.S in Zoology from Maryland University and a Ph.D. in Genetics from the University of George Washington.